^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | AZD4785 (KRAS inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Specific Targeting of KRAS Using a Novel High-Affinity KRAS Antisense Oligonucleotide in Multiple Myeloma
Published date:
11/06/2019
Excerpt:
AZD4785 significantly impaired proliferation and survival of KRAS-mutant MM cells in a dose- and time-dependent manner even in the presence of patients' derived BM-MSCs.
DOI:
https://doi.org/10.1182/blood-2019-124391
